CAM
CABA icon

Concorde Asset Management’s Cabaletta Bio CABA Stock Holding History

Concorde Asset Management’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-15,800
Closed -$131K – 129
2023
Q1 		$131K Buy
+15,800
New +$148K 0.15% 74

Other funds holding CABA

FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Concorde Asset Management's CABA Position: Q2 2023 in Review

Concorde Asset Management sold out of Cabaletta Bio (CABA) in Q2 2023, closing a stake of 15,800 shares — an estimated $131K sold.

Concorde Asset Management first reported a position in CABA in Q1 2023 and held it in 1 quarter. The position peaked at $131K in Q1 2023. 84 funds tracked by Wall St. Rank hold CABA as of Q2 2023.

  • Concorde Asset Management reported no remaining Cabaletta Bio position as of Q2 2023 after selling out during the quarter.
  • Concorde Asset Management sold 15,800 Cabaletta Bio shares in Q2 2023, an estimated $131K.
  • Concorde Asset Management first reported a position in Cabaletta Bio in Q1 2023 and held it in 1 quarter.
  • Concorde Asset Management's Cabaletta Bio position peaked at $131K in Q1 2023.
  • 84 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2023.

Based on Concorde Asset Management's 13F filing for Q2 2023, filed 25 Jul 2023.